九洲药业(603456) - 2020 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 25.28% to CNY 32,450,273.95 year-on-year[4] - Operating income decreased by 1.61% to CNY 391,511,397.99 compared to the same period last year[4] - Basic earnings per share decreased by 20.00% to CNY 0.04 compared to the same period last year[4] - The company reported a net profit from regular operations of CNY 31,051,843.25, an increase of 20.95% year-on-year[4] - Total operating revenue for Q1 2020 was CNY 391,511,397.99, a decrease of 1.0% compared to CNY 397,905,308.27 in Q1 2019[21] - Net profit for Q1 2020 was CNY 32,291,050.69, a decline of 25.0% from CNY 43,033,913.92 in Q1 2019[23] - Comprehensive income for Q1 2020 totaled CNY 33,074,707.52, compared to CNY 42,414,626.00 in Q1 2019, reflecting a decrease of 22.0%[24] Cash Flow - Net cash flow from operating activities decreased by 23.58% to CNY 80,898,428.63 year-to-date[4] - The net cash flow from operating activities was ¥80,898,428.63, down 23.6% from ¥105,857,616.48 in Q1 2019[28] - The company received cash from operating activities totaling ¥584,303,445.83, an increase of 6.6% from ¥548,318,154.89 in Q1 2019[28] - The company reported a total cash inflow from financing activities of ¥373,160,680.00, an increase of 17.6% from ¥317,327,400.00 in Q1 2019[29] - The net cash flow from financing activities increased by 246.71% to RMB 153,382,361.34 from RMB 44,238,860.84[14] Assets and Liabilities - Total assets increased by 6.96% to CNY 4,995,377,004.36 compared to the end of the previous year[4] - Total current assets rose to RMB 2,364,308,880.38 from RMB 2,018,340,764.04[16] - Total liabilities increased to ¥2,103,955,711.71 from ¥1,811,924,415.93, showing a rise of about 16.1%[18] - Current liabilities rose to ¥1,485,466,455.63, compared to ¥1,192,021,394.11, reflecting an increase of about 24.6%[17] - Total equity as of Q1 2020 was CNY 2,836,698,921.15, slightly up from CNY 2,833,349,401.10 in Q1 2019[21] Shareholder Information - The total number of shareholders at the end of the reporting period was 25,599[7] - The largest shareholder, Zhejiang Zhongbei Jiuzhou Group Co., Ltd., holds 32.58% of the shares, amounting to 262,471,824 shares[7] Government Support - The company received government subsidies amounting to CNY 7,451,987.90, which are closely related to its normal business operations[5] Inventory and Receivables - Inventory increased to RMB 916,851,411.19 from RMB 827,886,306.25[16] - Accounts receivable financing decreased by 63.48% to RMB 16,919,249.76 from RMB 46,327,527.04[10] - Accounts receivable decreased to ¥157,618,836.06 from ¥185,946,743.13, a decline of about 15.2%[19] Expenses - Management expenses increased by 50.09% to RMB 81,740,341.40 from RMB 54,460,020.76[12] - Research and development expenses for Q1 2020 were CNY 17,663,551.17, an increase of 9.9% from CNY 16,076,452.81 in Q1 2019[23] Investment Performance - The company reported a decrease in investment income, with a loss of CNY 5,041,322.67 in Q1 2020 compared to a loss of CNY 3,590,977.65 in Q1 2019[23] - The company recorded an investment loss of ¥2,551,416.76, an improvement from a loss of ¥7,569,268.57 in the same quarter last year[25] Financial Ratios - The weighted average return on equity decreased by 0.42 percentage points to 1.13%[4]